A detailed history of Deka Bank Deutsche Girozentrale transactions in Legend Biotech Corp stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 9,862 shares of LEGN stock, worth $394,775. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,862
Previous 11,572 14.78%
Holding current value
$394,775
Previous $514,000 6.61%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$43.55 - $59.88 $74,470 - $102,394
-1,710 Reduced 14.78%
9,862 $480,000
Q2 2024

Aug 08, 2024

BUY
$39.5 - $57.22 $70,784 - $102,538
1,792 Added 18.32%
11,572 $514,000
Q1 2024

Apr 24, 2024

SELL
$55.06 - $69.99 $5,065 - $6,439
-92 Reduced 0.93%
9,780 $555,000
Q4 2023

Jan 24, 2024

SELL
$57.25 - $69.74 $78,661 - $95,822
-1,374 Reduced 12.22%
9,872 $589,000
Q3 2023

Nov 13, 2023

SELL
$63.16 - $76.5 $53,243 - $64,489
-843 Reduced 6.97%
11,246 $756,000
Q2 2023

Jul 25, 2023

SELL
$46.28 - $75.01 $5,183 - $8,401
-112 Reduced 0.92%
12,089 $851,000
Q1 2023

Apr 24, 2023

BUY
$43.42 - $57.37 $63,697 - $84,161
1,467 Added 13.67%
12,201 $581,000
Q4 2022

Feb 01, 2023

SELL
$38.8 - $55.46 $120,202 - $171,815
-3,098 Reduced 22.4%
10,734 $532,000
Q3 2022

Nov 02, 2022

SELL
$38.15 - $57.1 $495 - $742
-13 Reduced 0.09%
13,832 $550,000
Q2 2022

Aug 03, 2022

BUY
$33.54 - $55.0 $48,934 - $80,245
1,459 Added 11.78%
13,845 $745,000
Q1 2022

Apr 28, 2022

BUY
$31.02 - $48.18 $110,152 - $171,087
3,551 Added 40.19%
12,386 $2.02 Million
Q4 2021

Feb 02, 2022

BUY
$41.14 - $56.98 $116,631 - $161,538
2,835 Added 47.25%
8,835 $417,000
Q4 2020

Mar 12, 2021

BUY
$25.8 - $32.39 $154,800 - $194,340
6,000 New
6,000 $173,000

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.7B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.